167 related articles for article (PubMed ID: 24777288)
21. Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer.
Yamamoto Y; Nishiyama Y; Ishikawa S; Nakano J; Chang SS; Bandoh S; Kanaji N; Haba R; Kushida Y; Ohkawa M
Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1610-6. PubMed ID: 17530250
[TBL] [Abstract][Full Text] [Related]
22. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
[TBL] [Abstract][Full Text] [Related]
23. Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET).
Ullrich RT; Zander T; Neumaier B; Koker M; Shimamura T; Waerzeggers Y; Borgman CL; Tawadros S; Li H; Sos ML; Backes H; Shapiro GI; Wolf J; Jacobs AH; Thomas RK; Winkeler A
PLoS One; 2008; 3(12):e3908. PubMed ID: 19079597
[TBL] [Abstract][Full Text] [Related]
24. Increase of [(18)F]FLT tumor uptake in vivo mediated by FdUrd: toward improving cell proliferation positron emission tomography.
Viertl D; Bischof Delaloye A; Lanz B; Poitry-Yamate C; Gruetter R; Mlynarik V; Ametamey SM; Ross TL; Lehr HA; André PA; Perillo-Adamer F; Kosinski M; Dupertuis YM; Buchegger F
Mol Imaging Biol; 2011 Apr; 13(2):321-31. PubMed ID: 20556524
[TBL] [Abstract][Full Text] [Related]
25. Thymidine Metabolism as a Confounding Factor for 3'-Deoxy-3'-
Schelhaas S; Wachsmuth L; Hermann S; Rieder N; Heller A; Heinzmann K; Honess DJ; Smith DM; Fricke IB; Just N; Doblas S; Sinkus R; Döring C; Schäfers KP; Griffiths JR; Faber C; Schneider R; Aboagye EO; Jacobs AH
J Nucl Med; 2018 Jul; 59(7):1063-1069. PubMed ID: 29476002
[TBL] [Abstract][Full Text] [Related]
26. Imaging cellular proliferation during chemo-radiotherapy: a pilot study of serial 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer.
Everitt S; Hicks RJ; Ball D; Kron T; Schneider-Kolsky M; Walter T; Binns D; Mac Manus M
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1098-104. PubMed ID: 19386444
[TBL] [Abstract][Full Text] [Related]
27. Imaging colon cancer response following treatment with AZD1152: a preclinical analysis of [18F]fluoro-2-deoxyglucose and 3'-deoxy-3'-[18F]fluorothymidine imaging.
Moroz MA; Kochetkov T; Cai S; Wu J; Shamis M; Nair J; de Stanchina E; Serganova I; Schwartz GK; Banerjee D; Bertino JR; Blasberg RG
Clin Cancer Res; 2011 Mar; 17(5):1099-110. PubMed ID: 21245090
[TBL] [Abstract][Full Text] [Related]
28. 3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography.
Barthel H; Cleij MC; Collingridge DR; Hutchinson OC; Osman S; He Q; Luthra SK; Brady F; Price PM; Aboagye EO
Cancer Res; 2003 Jul; 63(13):3791-8. PubMed ID: 12839975
[TBL] [Abstract][Full Text] [Related]
29. Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
Kahraman D; Scheffler M; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Holstein A; Dietlein M; Wolf J; Kobe C
J Nucl Med; 2011 Dec; 52(12):1871-7. PubMed ID: 22065872
[TBL] [Abstract][Full Text] [Related]
30. Response Monitoring with [
Heskamp S; Heijmen L; Gerrits D; Molkenboer-Kuenen JDM; Ter Voert EGW; Heinzmann K; Honess DJ; Smith DM; Griffiths JR; Doblas S; Sinkus R; Laverman P; Oyen WJG; Heerschap A; Boerman OC
Mol Imaging Biol; 2017 Aug; 19(4):540-549. PubMed ID: 27798786
[TBL] [Abstract][Full Text] [Related]
31. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.
Thureau S; Chaumet-Riffaud P; Modzelewski R; Fernandez P; Tessonnier L; Vervueren L; Cachin F; Berriolo-Riedinger A; Olivier P; Kolesnikov-Gauthier H; Blagosklonov O; Bridji B; Devillers A; Collombier L; Courbon F; Gremillet E; Houzard C; Caignon JM; Roux J; Aide N; Brenot-Rossi I; Doyeux K; Dubray B; Vera P
J Nucl Med; 2013 Sep; 54(9):1543-50. PubMed ID: 23918733
[TBL] [Abstract][Full Text] [Related]
32. Different modes of transport for 3H-thymidine, 3H-FLT, and 3H-FMAU in proliferating and nonproliferating human tumor cells.
Plotnik DA; Emerick LE; Krohn KA; Unadkat JD; Schwartz JL
J Nucl Med; 2010 Sep; 51(9):1464-71. PubMed ID: 20720049
[TBL] [Abstract][Full Text] [Related]
33. Induction of thymidine kinase 1 after 5-fluorouracil as a mechanism for 3'-deoxy-3'-[18F]fluorothymidine flare.
Lee SJ; Kim SY; Chung JH; Oh SJ; Ryu JS; Hong YS; Kim TW; Moon DH
Biochem Pharmacol; 2010 Nov; 80(10):1528-36. PubMed ID: 20723540
[TBL] [Abstract][Full Text] [Related]
34. 3'-Deoxy-3'-18F-fluorothymidine PET predicts response to (V600E)BRAF-targeted therapy in preclinical models of colorectal cancer.
McKinley ET; Smith RA; Zhao P; Fu A; Saleh SA; Uddin MI; Washington MK; Coffey RJ; Manning HC
J Nucl Med; 2013 Mar; 54(3):424-30. PubMed ID: 23341544
[TBL] [Abstract][Full Text] [Related]
35. 3'-Deoxy-3'-[
Schelhaas S; Heinzmann K; Honess DJ; Smith DM; Keen H; Heskamp S; Witney TH; Besret L; Doblas S; Griffiths JR; Aboagye EO; Jacobs AH
Mol Imaging Biol; 2018 Apr; 20(2):194-199. PubMed ID: 28971330
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography.
Yap CS; Czernin J; Fishbein MC; Cameron RB; Schiepers C; Phelps ME; Weber WA
Chest; 2006 Feb; 129(2):393-401. PubMed ID: 16478857
[TBL] [Abstract][Full Text] [Related]
37. Quantitative correlation at the molecular level of tumor response to docetaxel by multimodal diffusion-weighted magnetic resonance imaging and [¹⁸F]FDG/[¹⁸F]FLT positron emission tomography.
Honndorf VS; Schmidt H; Wehrl HF; Wiehr S; Ehrlichmann W; Quintanilla-Martinez L; Barjat H; Ricketts SA; Pichler BJ
Mol Imaging; 2014; 13():. PubMed ID: 25430886
[TBL] [Abstract][Full Text] [Related]
38. In vivo imaging of cell proliferation enables the detection of the extent of experimental rheumatoid arthritis by 3'-deoxy-3'-18f-fluorothymidine and small-animal PET.
Fuchs K; Kohlhofer U; Quintanilla-Martinez L; Lamparter D; Kötter I; Reischl G; Röcken M; Pichler BJ; Kneilling M
J Nucl Med; 2013 Jan; 54(1):151-8. PubMed ID: 23213198
[TBL] [Abstract][Full Text] [Related]
39. Repeatability of metabolically active volume measurements with 18F-FDG and 18F-FLT PET in non-small cell lung cancer.
Frings V; de Langen AJ; Smit EF; van Velden FH; Hoekstra OS; van Tinteren H; Boellaard R
J Nucl Med; 2010 Dec; 51(12):1870-7. PubMed ID: 21078791
[TBL] [Abstract][Full Text] [Related]
40. Metformin--an adjunct antineoplastic therapy--divergently modulates tumor metabolism and proliferation, interfering with early response prediction by 18F-FDG PET imaging.
Habibollahi P; van den Berg NS; Kuruppu D; Loda M; Mahmood U
J Nucl Med; 2013 Feb; 54(2):252-8. PubMed ID: 23376854
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
